What about Suzhou Kanglaide Biomedical Co., Ltd.?

Introduction: Suzhou Cornell Biomedical Co., Ltd. ("Suzhou Cornell" for short) was founded by a group of overseas doctoral teams with successful experience in new drug research and development and entrepreneurship at home and abroad in the pharmaceutical industry at the beginning of 20 12. The company is adjacent to Shanghai Taicang Biomedical Industrial Park.

Suzhou Kangruide focuses on developing innovative drugs related to autoimmune and tumor treatment with G protein-coupled receptor (GPCR) as the target. The company has self-developed GPCR monoclonal antibody drug technology and is committed to becoming a unique international leading enterprise in the field of GPCR monoclonal antibody drug research and development. We will further expand the technology platform and develop a series of related antibody drugs. At the same time, we will actively introduce technologies and products with global patent development rights, make use of the increasingly perfect biomedical R&D outsourcing CRO services, and rapidly promote the preclinical research of various new drug development projects, and apply for the approval of FDA and SFDA Clinical Research (IND) in China, and then complete further industrial development independently or in cooperation with large pharmaceutical companies to achieve the final market promotion.

Suzhou Kangruide has the global right to use some related drug development technologies and product patents, and applied to the US Patent Office for the global patent of GPCR monoclonal antibody technology independently developed. At present, Suzhou Cornell is actively promoting the pre-clinical development and industrialization of the new drug project of Arena Pharmaceutical Company of the United States, and the developed drugs will be used to treat allergic rhinitis and allergic dermatitis.

Company address:

2 15400 China, 5th Floor, xiang tang Development Building, No.3 Chaoyang East Road, Taicang City, Jiangsu Province.

Tel/Fax: 05 12-53577866

E-mail :qchang@connectpharm.com.

Company website:/

Legal Representative: Pan (Pan)

Date of establishment: 20 12-05-02

Registered capital: 465,438+0,288,326 yuan.

Location: Jiangsu Province

Unified social credit code: 913205855956746xw

Operating conditions: In operation.

Industry: scientific research and technical services

Company type: limited liability company (wholly owned by Taiwan, Hong Kong and Macao)

Number of employees: 100-499.

Enterprise address: No.6, Beijing West Road, Taicang Economic Development Zone

Business scope: engaged in research and development of new biomedical products and their technology development, technology exchange, technology introduction, technology promotion, technology transfer and technical services; Bioengineering, biomedical engineering and biomedical technology consulting and services. (Projects subject to approval according to law can only be operated after approval by relevant departments)